Evotec SE (EVO) stock
EVONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as EVOTF
$1.46−0.02 (-1.35%)
Close on Nov 18, 2026Market cap $519.11MP/E –Yield –
Evotec gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2025 it was €114.22M, down 0.6% from the year before. The highest annual figure on record is €175.05M in fiscal 2023.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €114.22M | -0.6% |
| FY2024 | Dec 31, 2024 | €114.88M | -34.4% |
| FY2023 | Dec 31, 2023 | €175.05M | +0.6% |
| FY2022 | Dec 31, 2022 | €174.07M | +14.9% |
| FY2021 | Dec 31, 2021 | €151.54M | +20.5% |
| FY2020 | Dec 31, 2020 | €125.74M | -5.4% |
| FY2019 | Dec 31, 2019 | €132.89M | – |
See a number that looks wrong?